Table 3.

Multivariable Adjusted Predictors of Oncologists' Awareness of Main LEs of All Chemotherapy Agents (n = 1,123)^*

Predictor	OR	95% CI
Age, years
< 40	1.00	Referent
40-49	1.13	0.78 to 1.64
50-59	1.09	0.73 to 1.62
≥ 60	0.73	0.47 to 1.14
Sex
Male	1.00	Referent
Female	1.14	0.78 to 1.70
Race/ethnicity
White	1.00	Referent
Asian/Pacific Islander	1.67	0.46 to 0.99
Hispanic	1.37	0.68 to 2.77
African American	0.58	0.24 to 1.37
Other	0.86	0.36 to 2.05
US trained
Yes	1.00	Referent
No	0.85	0.61 to 1.20
Board certified
No	1.00	Referent
Yes	1.68	1.07 to 2.65
Specialty
Medical oncology	1.00	Referent
Hematology/oncology	1.17	0.88 to 1.56
Other oncology	0.86	0.23 to 3.20
Location
Physician-owned practice	1.00	Referent
Large medical group/HMO	0.93	0.59 to 1.45
Hospital	0.97	0.69 to 1.35
Other	0.84	0.29 to 2.45
Percentage of uninsured patients
< 5	1.00	Referent
5-25	0.78	0.59 to 1.03
> 26	0.59	0.31 to 1.15
Percentage of time spent on patient care
< 50	1.00	Referent
51-90	1.90	1.24 to 2.91
> 90	1.82	1.08 to 3.07
No. of patients with breast or colon cancer per week
≤ 25	1.00	Referent
26-35	1.38	0.96 to 1.98
≥ 36	1.12	0.85 to 1.49
Self-reported confidence in knowledge of physical
Colon cancer
Very confident	1.00	Referent
Not/somewhat confident	1.08	0.71 to 1.65
Breast cancer
Very confident	1.00	Referent
Not/somewhat confident	0.61	0.39 to 1.94

NOTE. For doxorubicin, main LE is cardiac dysfunction; for paclitaxel and oxaliplatin, main LE is peripheral neuropathy; for cyclophosphamide, main LE used in model is premature menopause. Bold font indicates P < .05.

Abbreviations: LE, late or long-term effect; OR, odds ratio; PCP, primary care provider.

^*No. is slightly smaller than 1,130 because of missing information for variables of interest.